Study population
CAD
ADVERSE EVENTS, CORONARY ARTERY DISEASE, CAD
The study screened 48 volunteers for eligibility and 16 participants were included and randomized to receive dapagliflozin (n = 8) or placebo (n = 8) (Additional file In two patients, all FDG data were excluded from the analysis because post-treatment FDG PET/CT images were not evaluable.Demographic and baseline characteristics of each treatment group are summarized in Table Baseline characteristicsData are mean ± SEM. HbA1c, glycated hemoglobin; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration ratePatient compliance was high, and no study drug-related severe adverse events were registered.